Julie Delyon

Dr. Julie Delyon

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2013 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JDJulie Delyon
Julie Delyon
CMC. Mateus
C. Mateus
DLD. Lefeuvre
D. Lefeuvre
ELE. Lanoy
E. Lanoy
LZL. Zitvogel
L. Zitvogel
Caroline RobertCaroline Robert
Caroline Robert
Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program. In this prospective study, patients were treated between June 2010 and September 2011. Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy, and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kg every 3 weeks. Seventy-three patients were included. Median OS was 9.1 months (95% CI 6.4–11.3) from the start of ipilimumab. Immune-related adverse events were observed in 45 patients (62%), including 19 grade 3–4 events (26%). No drug-related death occurred. A lymphocyte count >1000/mm3 at the start of the second course and an increase in the eosinophil count >100/mm3 between the first and second infusions were correlated with an improved OS. Ipilimumab toxic effect is manageable in real life. Biological data such as lymphocyte and eosinophil counts at the time of the second ipilimumab infusion appear to be early markers associated with better OS.

1 December 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
CGCamille L. Gérard
Camille L. Gérard
JDJulie Delyon
Julie Delyon
AWA. Wicky
A. Wicky
KHK. Homicsko
K. Homicsko
Michel CuendetMichel Cuendet
Michel Cuendet
OMOlivier Michielin
Olivier Michielin

3 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JDJulie Delyon
Julie Delyon
CMChristine Mateus
Christine Mateus
TLThierry Lambert
Thierry Lambert
Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte–associated antigen 4, has been reported to improve overall survival in patients with metastatic melanoma.1 Major side effects include immune-related adverse events. We report a rare and severe case of ipilimumab-induced hemophilia A.

7 November 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DADimitri Arangalage
Dimitri Arangalage
JDJulie Delyon
Julie Delyon
MLMathilde Lermuzeaux
Mathilde Lermuzeaux
KEKenneth Ekpe
Kenneth Ekpe
SEStéphane Ederhy
Stéphane Ederhy
CLCéleste Lebbé
Céleste Lebbé

8 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Nicolas DumazNicolas Dumaz
Nicolas Dumaz
FJFanélie Jouenne
Fanélie Jouenne
JDJulie Delyon
Julie Delyon
Samia MourahSamia Mourah
Samia Mourah
Armand BensussanArmand Bensussan
Armand Bensussan
Céleste LebbéCéleste Lebbé
Céleste Lebbé
Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melanomas and highlight therapeutic targets. Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (BRAF) and neuroblastoma RAS viral oncogene homolog (NRAS) mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with BRAF and NRAS mutations. We show that in addition to being less frequent, BRAF and NRAS mutations are different in mucosal melanoma compared to cutaneous melanomas. Strikingly, the BRAF and NRAS mutation profiles in mucosal melanoma are closer to those found in cancers such as lung cancer, suggesting that mutations in mucosal melanoma could be linked to some genotoxic agents that remain to be identified. We also show that the atypical BRAF and NRAS mutations found in mucosal melanomas have particular effects on protein activities, which could be essential for the transformation of mucosal melanocytes.

10 March 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
JDJulie Delyon
Julie Delyon
LBLucie Biard
Lucie Biard
MRMarion Renaud
Marion Renaud
MRMatthieu Resche-Rigon
Matthieu Resche-Rigon
JGJérôme Le Goff
Jérôme Le Goff
CLCéleste Lebbe
Céleste Lebbe